| 1.43 -0.02 (-1.38%) | 04-26 12:49 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.96 | 1-year : | 2.15 |
| Resists | First : | 1.67 | Second : | 1.84 |
| Pivot price | 1.5 |
|||
| Supports | First : | 1.4 | Second : | 1.17 |
| MAs | MA(5) : | 1.45 |
MA(20) : | 1.54 |
| MA(100) : | 1.64  |
MA(250) : | 1.63 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 12.1 |
D(3) : | 13.9 |
| RSI | RSI(14): 35 |
|||
| 52-week | High : | 2.64 | Low : | 0.81 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ IOBT ] has closed above bottom band by 15.7%. Bollinger Bands are 42.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.5 - 1.51 | 1.51 - 1.52 |
| Low: | 1.4 - 1.41 | 1.41 - 1.42 |
| Close: | 1.43 - 1.45 | 1.45 - 1.46 |
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
Tue, 16 Apr 2024
IO Biotech, Inc. (NASDAQ:IOBT) Sees Large Decline in Short Interest - Defense World
Tue, 16 Apr 2024
IO Biotech, Inc. (NASDAQ:IOBT) Sees Large Decrease in Short Interest - MarketBeat
Wed, 03 Jan 2024
IO Biotech: A Phase 3 Company Getting No Respect (NASDAQ:IOBT) - Seeking Alpha
Tue, 19 Dec 2023
We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate - Yahoo Finance
Tue, 07 Nov 2023
This IO Biotech Insider Increased Their Holding In The Last Year - Yahoo Finance
Wed, 16 Aug 2023
Stonepine Capital Management, LLC Acquires New Stake in IO Biotech Inc - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 66 (M) |
| Shares Float | 26 (M) |
| Held by Insiders | 2.9 (%) |
| Held by Institutions | 81.1 (%) |
| Shares Short | 68 (K) |
| Shares Short P.Month | 54 (K) |
| EPS | -1.99 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.01 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -37.8 % |
| Return on Equity (ttm) | -63.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.39 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -72 (M) |
| Levered Free Cash Flow | -42 (M) |
| PE Ratio | -0.73 |
| PEG Ratio | 0 |
| Price to Book value | 0.7 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.32 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|